Carrier Screening Market

Global Carrier Screening Market Size

The size of the global carrier screening market was worth USD 2.43 billion in 2025. The global market is anticipated to grow at a CAGR of 10.12% from 2026 to 2034 and be worth USD 5.79 billion by 2034 from USD 2.68 billion in 2026.

Carrier screening is performed on an individual who shows no symptoms of a genetic disorder but may be at risk of passing it on to the next generation of potentially developing the disease later in life. A carrier has inherited a normal and a variable gene for a disease- or trait-associated gene, one from each parent. A sample of blood, saliva, or tissue from the cheek is required to check the status of carrier testing. The results of the test can be either negative or positive. Generally, the partner most likely to be a carrier is tested first. If test results show that the first partner is not a carrier, no additional testing is needed. Once you have had a carrier screening test for a specific disorder, you do not need to be tested again for that particular disease carrier screening test has been done. Carrier screening is mainly done before pregnancy. It gives you a greater range of options and more time to make decisions.

MARKET DRIVERS

The growing prevalence of genetic diseases and the importance of early disease detection and prevention majorly drive the growth of the carrier screening market. Genetic diseases can have a significant impact on individuals and families. Realizing the same, several couples have been showing interest in performing carrier screening to evaluate the possibility of carrying genetic variations to their children. The awareness and adoption of carrier screening among couples has increased significantly in recent years, and these procedures have been playing an important role in making crucial reproductive decisions such as opting for prenatal testing or exploring assisted reproductive technologies. This trend is likely to fuel in the coming years and drive the carrier screening market growth.

Increased demand for personalized medicine, early identification and prevention, and applications of screening tests for genetic disorders are likely to propel the global carrier screening market forward. Several genetic diseases are found in early pregnancy. Nowadays, pregnant women are performing carrier screening to determine the risk of a child inheriting genetic diseases from the parents. The aforementioned factors are expected to fuel the growth of the global carrier screening market. Carrier testing can provide information about some risks of having a child with a genetic condition. Identification of the risk before the onset of symptoms is called predictive testing. Growing awareness of carrier screening, the high risk of chromosomal abnormalities, and technological developments in carrier screening

An increase in the prevalence of fetal chromosomal abnormalities, increased use of standardized testing for genetic disorders, technological advancements such as the development of next-generation sequencing (NGS) techniques for genetic disease screening and DNA sequencing, and investments in R&D for advancement in carrier screening are further anticipated to strengthen the growth rate of the market during the forecast period. Furthermore, increasing funding from government & private bodies for large-scale carrier screening projects and a reduction in the cost of screening notably contribute to the growth of the global market. In addition, factors such as an increase in the incidence of genetic diseases, an increase in the availability & affordability of tests, a large number of biotechnology firms, and a rise in the number of advanced product launches all drive the market forward in the future.

MARKET RESTRAINTS

The lack of standardization guidelines for carrier screening and a shortage of qualified workers could somewhat hinder market expansion. In addition, regulatory difficulties in the field of carrier screening and the lack of high-level complexity testing centers are significant challenges in the carrier screening market. Limited awareness and understanding among the general population about carrier screening and its benefits, social and cultural stigmas associated with genetic diseases and carrier status, lack of access to carrier screening services in certain regions or healthcare systems, particularly in low-resource settings, high cost of carrier screening tests and limited insurance coverage are some of the other major roadblocks to the growth of the carrier screening market.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Type Insights

Based on the type, the molecular screening test segment is predicted to account for the major share of the worldwide market during the forecast period. Molecular screening tests are common. It is used to find DNA abnormalities in genetic information and detect mutations that might cause heart issues, pre-leukemia, auditory impairments, and Down syndrome. Additionally, it also helps to provide adequate prenatal and reproductive healthcare, which aids in the management of heritable disorders. Advancements in genetic testing technologies, such as next-generation sequencing, growing demand for carrier screening for a wide range of genetic disorders, rising awareness among healthcare professionals and patients about the benefits of molecular screening in identifying carrier status, drive the growth of the molecular screening test segment. The expansion of genetic counseling services, continuous research and development efforts to enhance the sensitivity and specificity of molecular screening tests, and rapid adoption of molecular screening by reproductive healthcare providers to offer personalized counseling and guidance for reproductive decision-making further contribute to the segmental growth.

By Technology Insights

Based on technology, the DNA sequencing segment is expected to account for the leading share of the global market during the forecast period. The advancements in genetic analysis tools, such as assays based on next-generation sequencing and microarray technologies, molecular diagnostics, and advances in the type of heritable diseases, drive the growth of the DNA sequencing segment. An increasing number of advancements in Next-Generation Sequencing (NGS) technologies, growing availability of comprehensive sequencing panels that can detect a wide range of genetic variations associated with carrier status, and rising demand for personalized medicine and precision healthcare are driving the adoption of DNA sequencing for carrier screening and propelling the growth of the DNA sequencing segment.

By End-User Insights

Based on the end-user, the hospital segment is expected to capture the leading share of the worldwide market during the forecast period. This is because hospitals are the first place patients tend to visit after the detection of a particular ailment. In addition, the increasing patient population, the rise in advanced diagnostic tests, and the rise in the medical reimbursement for clinical tests performed in hospitals are some of the major factors stimulating the growth of the end-user segment.

REGIONAL ANALYSIS

Geographically, the North American market led the market for carrier screening worldwide in 2022. Factors driving the region such as the presence of well-established healthcare systems in the U.S. and Canada, wide access to advanced screening techniques, high and growing demand for the early detection of genetic disorders among the population, availability of mass genetic testing programs, increasing number of awareness programs, and the rising incidence of chromosomal disorders. According to the WHO, genetic disorders are the primary reason for newborn mortality in the United States, accounting for nearly 2.4 million children dying in their first month worldwide in 2019. Around 6700 newborns die daily, accounting for 47 percent of all child mortality under five, up from 40 percent in 1990. As per the report of the Centres for Disease Control and Prevention report in 2020, among children with Sickle cell disease, 1% died due to Sickle cell-related causes during the first three years of life. The danger of fetal chromosomal abnormalities increases gradually up to the age of 30 and rises gradually beyond that, as reported by the American Academy of Family Physicians. This growth in average maternal age is estimated to boost the incidence of chromosomal abnormalities, leading to increased demand for carrier screening.

Asia Pacific market is expected to have the highest CAGR in the worldwide market during the forecast period. High birth rates in India and China are predicted to provide huge benefits to developers, provided the tests available are cost-effective. Focusing on these emerging markets is likely to enable prenatal and newborn genetic testing developers and providers to record high revenue growth. The presence of a large population base with a high burden of genetic disorders, increasing awareness and demand for prenatal and carrier screening, growing investments in genetic testing and research, expansion of market players in the region and increasing number of initiatives from the governments of European countries to improve healthcare access and affordability drive the growth of the APAC carrier screening market.

Europe is also predicted to grow in the carrier screening market in the coming years due to the region's launches and approvals of new screening tests. The growing incidence of genetic disorders, favorable government policies, and regulations, increasing investments in genetic research and screening programs and well-established healthcare systems promotes the carrier screening market growth in Europe. The rising awareness among the population and increasing number of collaborations between research institutes and industry players further boost the growth rate of the European market.

Latin America is estimated to account for a notable share of the global market during the forecast period. Factors such as the growing awareness about genetic disorders and carrier screening, rapid adoption of genetic testing, and prenatal screening. The initiatives of the Latin American governments to improve healthcare access and affordability and high prevalence of certain genetic disorders in specific populations drive the carrier screening market in Latin America.

TOP COMPANIES IN THIS MARKET

Some of the companies that are playing a dominating role in the global carrier screening market include

• Abbott Laboratories
• 23andMe Inc.
• Autogenomics Inc.
• Danaher Corporation
• Fulgent Genetics Inc.
• Myriad Genetics
• OPKO Health
• Quest Diagnostics Incorporated
• Eurofins Scientific
• Illumina Inc.
• Luminex Corporation
• Invitae Corporation
• MedGenome
• Natera Inc.
• Thermo Fisher Scientific Inc.
• Roche AG
• Sequenom Inc.
• True Health

GLOBAL CARRIER SCREENING MARKET NEWS

• The launching of at-home reproductive genetic testing products, Peaches&Me™ and 23Pears™, in all 50 states was announced by Mitera.
• In 2020, Quest Diagnostics announced the acquisition of Blueprint Genetics in an all-cash equity transaction. Blueprint Genetics is a leading specialty genetic testing company specializing in gene variant interpretation based on next-generation sequencing (NGS) and proprietary bioinformatics.

MARKET SEGMENTATION

This research report on the global carrier screening market has been segmented and sub-segmented based on the type, technology, end-user, and region.

By Type

• Molecular Screening Test
• Biochemical Screening Test

By Technology

• DNA Sequencing
• Polymerase Chain Reaction
• Microarray

By End-User

• Hospitals
• Reference Laboratories
• Physician Offices & Clinics

By Region

• North America
• Europe
• Asia-Pacific
• Middle East Africa
• Latin America